CaribPR Wire

PHILADELPHIA, Feb. 22, 2019 /PRNewswire-HISPANIC PR WIRE/ – The following statement is being issued by Berger Montague regarding the Dental Supplies Antitrust Litigation.

An $80 million cash Settlement has been reached in a lawsuit known as In re Dental Supplies Antitrust Litigation, No 16-cv-00696 (E.D.N.Y.), against Henry Schein, Inc. (”Schein”), Patterson Companies, Inc. (”Patterson”), and Benco Dental Supply Company (”Benco”) (collectively, “Defendants”). The lawsuit alleges that the Defendants agreed not to compete on prices for Dental Products. The Defendants deny these claims, insist they did nothing wrong, and a judge has not decided who is right.

Who’s Included?
The Settlement is for a “Class” that includes anyone in the U.S. who purchased Dental Products directly from Defendants or Burkhart during the Class Period: August 31, 2008 to March 31, 2016.

What does the Settlement provide?
The Defendants will pay $80 million into a “Settlement Fund.” The settlement proceeds, net of all court-approved fees and costs, will be allocated pro rata, based on relative purchase amounts. For more information on payouts, please consult paragraphs 25-30 of the November 12, 2018, Declaration of Eric L. Cramer and/or the Plan of Allocation (when it is available) on the settlement website. Class Counsel will be asking the Court to approve a fee of up to 1/3 of the Settlement amount, plus reimbursement of costs, and service awards for the named plaintiffs. That Fee Application will be available on the settlement website on March 24, 2019.

How can I receive benefits?
If the Settlement is approved, you will receive a Claim form in the mail (it will also be available on the Settlement website). You must file a claim by September 19, 2019 in order to receive a payment.

How can I exclude myself or object?
If you want to sue the Defendants yourself, you must exclude yourself from the Settlement by April 18, 2019, in which case you will not receive a payment from the Settlement. If you do not exclude yourself, you may file an objection to the Settlement or any aspect of it by April 18, 2019.

More complete information, including the Settlement Agreement and release of claims, instructions on filing a claim (when a claim form becomes available), Excluding, and Objecting is available on the settlement website, www.DentalSuppliesAntitrustClassAction.com or you may call toll free 1-844-367-8807.

When will the Court decide?
A Fairness Hearing will be held on May 22, 2019 at 10:00 a.m. at the U.S.D.C. for the Eastern District of NY, 225 Cadman Plaza E, Brooklyn, NY 11201 in Courtroom 8D S to consider whether to approve the Settlement and Fee Application. You may, at your own expense appear at the Hearing, but you don’t have to.

Click Here for More Information »

Click Here for More Information »

CaribPR Wire, NEW YORK, NY, Mon. July 16, 2018: Mobiquity Technologies, Inc. (OTCQB:MOBQ), a leading mobile location data intelligence company today announced a platform partnership with SoMedia, a leading international media technology solutions company focusing on Latin America, whose clients include Fortune 500 companies.  The partnership gives SoMedia access to Mobiquity Networks’ platform to run media campaigns for their clients and gives Mobiquity a strong initial foothold in Latin America and an immediate new revenue stream.

The Mobiquity platform provided to SoMedia is a full end-to-end media solution, which includes its own AdServer, DSP, DMP and Ad-quality control solution.  Mobiquity’s platform is also integrated into hundreds of supply and demand side partners and offers extremely precise location-based audiences and targeting, machine learning for optimization and post campaign attribution.

“SoMedia is a cutting-edge media company with an outstanding staff and impressive client roster. We believe this relationship will be extremely beneficial to all parties and we look forward to working with SoMedia in both the USA and Latin America to bring a cost-effective media solution to their clients,” stated Mobiquity Technologies CEO, Dean Julia. He continued, “As we recently announced in our Shareholder update, we are highly focused on getting to cash flow positive by year end.  I believe this new revenue stream will get us one step closer to achieving that goal.”

Andrea Tonicelo founder of SoMedia, said “We always put our clients’ needs first and our goal is to provide outstanding campaign results, with full transparency and increased ROI for our clients, and I believe working with Mobiquity Networks and their very impressive state-of-the-art platform allows us to do that.”

About Mobiquity Networks (www.mobiquitynetworks.com)

Mobiquity Networks, a wholly owned subsidiary of Mobiquity Technologies, Inc. (MOBQ), is a next generation mobile location data intelligence company.  The company provides precise, unique, at-scale location data and insights on consumer’s real-world behavior and trends for use in marketing and research. With our combined exclusive data set and first party location data via our advanced SDK; Mobiquity Networks provides one of the most accurate and scaled solution for mobile data collection and analysis.

About SoMedia (www.sogroup.media)

SoMedia is a technological media solutions company. Every day billions of consumer interactions happen around the world, with diverse interests and behaviors. We exist to connect this audience to your brand at the right time with the right message. Reach customers who are genuinely interested in what your company offers. We target scale data, using as a basis content with which they actively interact, engaging and increasing their conversion potential. Not only with technology but with constant strategic intelligence.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements express or implied by such forward-looking statements. The forward‐looking statements are subject to risks and uncertainties including, without limitation, changes of competition, possible loss of customers, and the company’s ability to attract and retain key personnel.

Mobiquity Networks incorpora a SoMedia a la nómina de clientes

CARIBPR WIRE, NUEVA YORK, July 17, 2018:  Mobiquity Technologies, Inc. (OTCQB:MOBQ), una empresa líder en inteligencia de datos de ubicación móvil, anunció hoy una asociación de plataformas con SoMedia, una empresa internacional líder en soluciones de tecnología de medios concentrada en Latinoamérica, entre cuyos clientes se incluyen empresas que integran la lista Fortune 500.La asociación le proporciona a SoMedia acceso a la plataforma de Mobiquity Networks para ejecutar campañas de medios para sus clientes y le concede a Mobiquity una sólida posición inicial en Latinoamérica y una nueva fuente inmediata de ingresos.

La plataforma de Mobiquity proporcionada a SoMedia es una solución completa e integral de medios, que incluye su propia solución de control de calidad de servidores AdServer, plataformas de gestión de datos (data management platform, DMP), plataformas orientadas a la demanda (demand side platforms, DSP) y anuncios publicitarios.La plataforma de Mobiquity también está integrada con cientos de socios de los sectores de la oferta y la demanda y ofrece audiencias y selección de objetivos basadas en la ubicación sumamente precisas, aprendizaje automático para lograr la optimización y atribución posterior a la campaña.

“SoMedia es una empresa de medios de vanguardia con un personal excepcional y una sorprendente nómina de clientes. Consideramos que esta relación será sumamente beneficiosa para todas las partes y esperamos trabajar con SoMedia tanto en los EE. UU. como en Latinoamérica para ofrecer una solución de medios rentable a sus clientes”, declaró el director ejecutivo de Mobiquity Technologies, Dean Julia. Agregó: “Como anunciamos recientemente en nuestra actualización para accionistas, estamos muy enfocados en obtener un flujo de caja positivo hacia fin de año.Creo que esta nueva fuente de ingresos nos acercará aún más a lograr ese objetivo”.

Andrea Tonicelo, fundadora de SoMedia, afirmó: “Siempre priorizamos las necesidades de nuestros clientes y nuestro objetivo es proporcionar resultados de campaña destacados, con total transparencia y un mayor retorno de la inversión para nuestros clientes, y creo que trabajar con Mobiquity Networks y su impresionante plataforma de vanguardia nos permite lograrlo”.

Acerca de Mobiquity Networks (www.mobiquitynetworks.com)

Mobiquity Networks, una subsidiaria de propiedad absoluta de Mobiquity Technologies, Inc. (MOBQ), es una empresa de inteligencia de datos de ubicación móvil de última generación.La empresa proporciona datos de ubicación precisos, únicos y a escala, así como información sobre el comportamiento y las tendencias de los consumidores en el mundo real para su uso en marketing e investigación. Con un conjunto de datos exclusivos combinados y datos de ubicación de origen a través de nuestro kit de desarrollo de software (Software Development Kit, SDK) avanzado, Mobiquity Networks ofrece una de las soluciones más precisas y a escala para la recopilación y el análisis de datos móviles.

Acerca de SoMedia (www.sogroup.media)

SoMedia es una empresa de soluciones de medios tecnológicos. Todos los días, se producen miles de millones de interacciones con los consumidores en todo el mundo, con diversos intereses y comportamientos. Existimos para vincular a este público con su marca en el momento adecuado y con el mensaje correcto. Comuníquese con los clientes que tengan un interés genuino por lo que ofrece su empresa. Tenemos como objetivo los datos a escala, y utilizamos como base el contenido con el que interactúan de forma activa, lo que aprovecha y aumenta su potencial de conversión. No solo con tecnología sino también con inteligencia estratégica constante.

DECLARACIÓN DE PROTECCIÓN LEGAL CONFORME A LA LEY DE REFORMA DE LITIGIOS SOBRE VALORES PRIVADOS DE 1995

Determinados enunciados de este comunicado de prensa constituyen “declaraciones a futuro” conforme a la Ley de Reforma de Litigios sobre Valores Privados (Private Securities Litigation Reform Act) de 1995. Dichas declaraciones a futuro implican riesgos conocidos y desconocidos, incertidumbres y otros factores, que pueden causar que los resultados, el desempeño o los logros reales de la empresa se diferencien sustancialmente de cualquier resultado, desempeño o logro futuro expreso o implícito en estas declaraciones. Las declaraciones a futuro están sujetas a riesgos e incertidumbres que incluyen, entre otros, cambios en la competencia, posible pérdida de clientes y la capacidad de la empresa de atraer y retener personal clave.

Click Here for More Information »

NEW YORK, April 5, 2018 /PRNewswire-HISPANIC PR WIRE/ –

I f You Purchased Solodyn® and/or Its Generic Equivalent
You Could Get Money from a Class Action Lawsuit Settlement

A proposed $23 million settlement has been reached in a class action lawsuit involving the antibiotic drug Solodyn®. The lawsuit claims that Medicis Pharmaceutical Corp., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (the “Defendants”) violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn® off the market. The Defendants deny this. No one is claiming that Solodyn® is unsafe or ineffective.

W ha t does the settlement provide?

To settle the lawsuit, Medicis Pharmaceutical Corp. has agreed to pay $23 million into a Settlement Fund to settle all claims in the lawsuit brought on behalf of consumers and health insurers known as third-party payors.

Class Counsel will ask the Court to award attorneys’ fees in an amount not to exceed one-third of the Settlement Fund, plus interest, litigation expenses and incentive payments to the Class Representatives.   After these deductions, the remainder of the Settlement Fund will be distributed pro rata to Class Members who file a valid claim form. The amount of money you are eligible to receive will depend on how much you (and other consumers) paid for Solodyn® or generic versions of Solodyn®.

W h o is included?

Generally, you are included in the Classes if you purchased, paid and/or provided reimbursement for some or all of 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn® and/or its generic equivalent prescription in AL, AK, AZ, AR, CA, FL, HI, ID, IL, IA, KS, LA, ME, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OK, OR, RI, SD, TN, UT, VT, WA, WV, WI, WY, DC and PR, in tablet form, from July 23, 2009 through February 25, 2018, inclusive. Certain third-party payors are also members of the Classes.

You are NOT a member of the Classes if: you paid a “flat co-payment” for all of your prescription drug purchases regardless of whether they are brand or generic; you are one of the Defendants or an officer, director, manager, employee, subsidiary, or affiliate of any Defendant(s); you purchased only directly from Defendants or for resale purposes; you purchased or received Solodyn® or its generic equivalent only through a Medicaid program; you are a Pharmacy Benefit Manager, or you are the judge in this lawsuit or a member of the judge’s immediate family.

How do I get a payment?

You must submit a Claim Form by July 31, 2018 to be eligible for a payment. The Claim Form, and instruction on how to submit it, are available at www.SolodynCase.com or by calling 1-800-332-7414.

W ha t are my other rights?

If you are a Class Member, you may comment on or object to the proposed Settlement. To do so, you must act by May 28, 2018. Details on how to comment or object are at www.SolodynCase.com.

The Court will hold a hearing tentatively set for 2:00 p.m. on July 11, 2018, to consider whether the Settlement and all of the terms are fair, reasonable, and adequate. These deadlines may be amended by Court Order, so check the litigation website noted below.

F o r More Information or to Request a Claim Form
V is i t w w w. So l odyn C a s e.c o m
C a l l 1-800-332-7414

Source: Motley Rice LLC

Click Here for More Information »

CaribPR Wire, NEW YORK, Feb. 26, 2018: The Board of ARBITRADE is pleased to announce that the role of the Chairman of the Board of Directors, Leonard Schutzman, has been expanded to Chief Executive Officer.

Mr. Schutzman had a distinguished thirty-year career at PepsiCo, Inc., serving in a variety of leadership positions including Treasurer of PepsiCo Corporate, and Chief Financial Officer of PepsiCo, Inc., Frito-Lay and Taco Bell.

Commenting on his appointment, Mr. Schutzman said he was excited to take on this leadership role in an industry that will grow exponentially on a global scale.  “It is a time of growth for our companies and at Arbitrade, I am fortunate to be supported by some of the best minds in the Cryptocurrency. This, and the combination of our distinctive strategy and proprietary software, will allow me to put together a world class management team and Board of Directors. I am confident that Arbitrade has the potential to be a best–of–breed Cryptocurrency company.”

ARBITRADE, through its proprietary software and strategic partnerships, plans to be in all segments of the cryptocurrency business, including currency mining, trading (The ARBITRADE Exchange) gift cards, debit cards, money transfer and Point of Sale processing.

ACTUALIZACIÓN- Ex ejecutivo sénior de PepsiCo es designado director ejecutivo de Arbitrade

CaribPR Wire, NUEVA YORK, Feb. 27, 2018: La Junta Directiva de ARBITRADE se complace en anunciar que la función de presidente de la Junta Directiva de Leonard Schutzman se amplió para incluir la de director ejecutivo.

El Sr. Schutzman tuvo una distinguida carrera de treinta años en PepsiCo, Inc., en donde se desempeñó en una variedad de puestos de liderazgo, incluidos el de tesorero de PepsiCo Corporate y el de director financiero de Pepsi Cola International, Frito-Lay y Taco Bell.

En relación con su designación, el Sr. Schutzman expresó que estaba entusiasmado de asumir este rol de liderazgo en una industria que crecerá exponencialmente a nivel mundial. “Es un momento de crecimiento para nuestras compañías y en Arbitrade, tengo la suerte de contar con el apoyo de las personas más capacitadas en el área de las criptodivisas. Esto, en combinación con nuestra estrategia distintiva y nuestro software de propiedad exclusiva, me permitirán armar un equipo gerencial y una Junta Directiva de primer nivel. Estoy seguro de que Arbitrade tiene el potencial de ser una de las mejores compañías de criptodivisas”.

ARBITRADE, a través de su software de propiedad exclusiva y asociaciones estratégicas, planea estar presente en todos los segmentos del negocio de las criptodivisas, incluidas la generación de monedas (currendy mining), las tarjetas de regalo comerciales (ARBITRADE Exchange), las tarjetas de débito, las transferencias de dinero y el procesamiento de puntos de venta.

Click Here for More Information »

Click Here for More Information »

NEW YORK, April 28, 2017 /PRNewswire-HISPANIC PR WIRE/ –

If You Purchased Solodyn and/or Its Generic Equivalent Partial Settlements of a Class Action Lawsuit May Affect Your Rights

Partial settlements have been reached in a class action lawsuit involving the antibiotic drug Solodyn. The lawsuit claims that Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (the “Defendants”) violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The Defendants deny this. No one is claiming that Solodyn is unsafe or ineffective.

WHAT DO THE SETTLEMENTS PROVIDE?

To settle the lawsuit, Lupin Pharmaceuticals Inc. and Lupin Limited (”Lupin Defendants”) and Sandoz Inc. (”Sandoz”) have each agreed: (a) that they would be willing to provide certain witnesses that Plaintiffs could call and a declaration that the Plaintiffs could use during the Solodyn case involving the overall End-Payor Class, other Plaintiffs, and the Non-Settling Defendants; and (b) to deposit $625,000 and $1.75 million, respectively, into Settlement Funds. If the Settlements are approved by the Court and become final, the Settlement Funds, inclusive of interest, will be used to: (1) pay for costs and expenses incurred or to be incurred by Counsel in continuing the lawsuit against Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., and Impax Laboratories, Inc. (the “Non-Settling Defendants”); (2) cover taxable costs and taxes payable on the Settlement Funds; (3) pay for notice and other expenses; and (4) pay for service awards not to exceed $10,000 to the class representatives in recognition of their efforts to date on behalf of the Classes. Any remainder in the Settlement Funds, after the payment of the above expenses, shall be distributed to the End-Payor Class for the Lupin Settlement and the End-Payor Class for the Sandoz Settlement in a manner approved by the Court at the conclusion of the litigation. The Settlement Agreements, available at the website www.SolodynCase.com contain more details. These Settlements involve only the Lupin Defendants and Sandoz. The case will continue against the Non-Settling Defendants.

WHO IS INCLUDED IN THE CLASSES?

Generally, you are included in the Classes if you purchased, paid and/or provided reimbursement for some or all of a Solodyn and/or its generic equivalent prescription in the United States and its territories, including Puerto Rico, in tablet form, from July 23, 2009, onward. Certain third-party payors are also members of the Classes.

You are NOT a member of the Classes if: you paid a “flat co-payment” for all of your prescription drug purchases regardless of whether they are brand or generic; you are one of the Defendants or an officer, director, manager, employee, subsidiary, or affiliate of any Defendant(s); you purchased only directly from Defendants or for resale purposes; you purchased or received Solodyn or its generic equivalent only through a Medicaid program; you are the judge in this lawsuit or a member of the judge’s immediate family; and/or you previously excluded yourself from the overall End-Payor Class.

YOUR RIGHTS AND OPTIONS

If you are a Class Member, you have the right to exclude yourself (to opt-out) from one or both of the Settlements no later than June 12, 2017. You may also comment on or object to one or both of the proposed Settlements. To do so, you must act by June 12, 2017. Details on how to request exclusion, comment, or object are at www.SolodynCase.com.

The Court will hold a hearing tentatively set for 3:00 p.m. on November 27, 2017, to consider whether the Settlements and all of their terms are fair, reasonable, and adequate. Please check the website for updates.

FOR MORE INFORMATION
Visit www.SolodynCase.com
Call 1-800-332-7414

Click Here for More Information »

Click Here for More Information »

Sign, Graphics and Visual Communications Franchisor Seeks Franchise Candidates throughout Florida and the Caribbean

CARROLLTON, Texas, Feb. 13, 2017 /PRNewswire-HISPANIC PR WIRE/ – FASTSIGNS International, Inc., franchisor of FASTSIGNS^®, the leading sign, graphics and visual communications franchise, announced today that it is attending and sponsoring at the National Business Media Show from Feb. 16 to 18, 2017 at the Fort Lauderdale Convention Center. The company is recruiting franchisees, promoting expansion throughout the state of Florida and across the Caribbean, with a focus on targeting conversion and co-branded locations.

“With the increasingly high demand for visual communication needs worldwide, FASTSIGNS is looking to expand our presence throughout Florida and across the Caribbean,” said Mark Jameson, EVP of Franchise Support and Development, FASTSIGNS International, Inc. “We look forward to utilizing our presence at the National Business Media Show in Fort Lauderdale to network with potential franchisees and discuss the impact that our brand has to offer business owners within the print and signage industry.”

Local entrepreneurs are invited to meet with the brand’s franchise development team at booth #2425 to learn more about conversion and co-branded location opportunities throughout the state of Florida and across the Caribbean. The fast-growing brand currently has 49 locations in Florida plus 7 in Development, three in Puerto Rico and one in Grand Cayman and recently signed a Master Agreement for expansion into the USVI and the Dominican Republic but is looking to expand with additional centers throughout Florida, with an emphasis on the Treasure Coast up to Jacksonville, as well as throughout the Caribbean Islands, including Barbados, Bermuda, Jamaica and Trinidad and Tobago. Due to the ongoing worldwide need for visual communications and digital signage technology, the company expects to open a projected 45 locations in 2017.

For information about the FASTSIGNS franchise opportunity, contact Mark Jameson ([email protected] or 214-346-5679) or download an eBook that explores the FASTSIGNS franchise opportunity at http://amzn.to/1FrnDJu.

About FASTSIGNS ^®
FASTSIGNS International, Inc. is the largest sign and visual communications franchisor in North America, and is the worldwide franchisor of more than 650 independently owned and operated FASTSIGNS^® centers in nine countries including the US, Canada, England, Saudi Arabia, UAE, Grand Cayman, Mexico and Australia (where centers operate as SIGNWAVE^®).

FASTSIGNS locations provide comprehensive sign and visual graphic solutions to help companies of all sizes and across all industries attract more attention, communicate their message, sell more products, help visitors find their way and extend their branding across all of their customer touch points including décor, events, wearables and marketing materials. Learn more about sign and visual graphic solutions or find a location at fastsigns.com. Follow the brand on Twitter @FASTSIGNS, Facebook at facebook.com/FASTSIGNS or LinkedIn: www.linkedin.com/company/fastsigns.

Click Here for More Information »

Click Here for More Information »

FOR IMMEDIATE RELEASE

CaribPR Wire, STUTTGART, Germany, Weds. Jan. 7, 21014: The Jamaican Duo “Voice Mail” has released a new album on Jan. 5^th. Voice Mail is known for harmony-loaded vocals, to spread excitement for dancing and for a focus on the good things in life! The album is entitled “Next Level” and features 14 tracks of which 3 had been previously released.

Track List:

1. I’m Going Out

2. Party Commander

3. Do What I Wanna

4. Summertime

5. United

6. I Got Love

7. Party Is On

8. Spaceship

9. Here And Now

10. If I Could

11. Attention

12. Let Go

13. Jump Up

14. One Life to Live

“For this record, we’ve decided to explore untapped territories,” said Craig Jackson of Voice Mail. “We wanted to do something different, something with influences from other countries and musical styles. That’s why we partnered with two overseas producers: Dave Edwards from Brooklyn, New York and The Titans from Stuttgart, Germany. There were no limitations as to what music genre to go with. We just went into the studio and experimented with different instrumentals to see where our creativity flowed. It was a very intuitive production process. I think the result can hardly be described in terms of a genre. I urge you to listen to the songs and tell us what you think it is?”

“The production process for ‘Next Level’ was in a sense unique. We’ve tried to identify ‘white space opportunities’ between popular songs that exist today in order to drive innovation for tomorrow. Our approach to enable innovation & invention was based on giving both producers and artists creative freedom within the production process,” said Michael Freudenberger, CEO Captivate Music.

“Voice Mail frequently flew to New York or Germany and usually we spent a week in the studio, recording one song a day, every day. For those recordings we used random instrumentals from the Internet. Later, the producers screened the vocals to decide on which song they want to work. Once they were finished with a first mix that sometimes only featured a hook or verses, Voice Mail went back to the studio (in Jamaica) to record more material. The forth and back continued as long as it was necessary to get everyone satisfied. The end results were later mastered at Sterling Sound in NYC.“

“Next Level” stands for a reinvention of not only our music but also our image. Reinvention is crucial to capture people’s attention and have them remain interested,” said Kevin Blair of Voice Mail. “Our broader focus is more towards that than to fulfill every expectation of people that are familiar with the band. Since we lost one of our members, we’ve had to reposition “Voice Mail”. Our audience today is loyal but also in constant flux and that’s not necessarily a bad thing. I think there are two categories of fans we can attract with this album.

“Over the past couple of years, pop and EDM music has become extremely popular in Jamaica. At many Jamaican parties today, DJs play a mix between music from local artists and that of global artists (such as Rihanna, Nicki Minaj or Flo Rida). Our intention here is to unite both worlds, the local with the global. I think Jamaica is ready for an act that bridges the gap.

“On the other hand, we see artists in the U.S. using Dancehall elements in their music. Every time I hear that I ask myself, why is Jamaica not delivering that music to international consumers? There are endless talents in Jamaica and there is the demand from international audiences for Dancehall drums, vocals etc. So our secondary target group are those fans.”

The album is a joint venture between Scikron Entertainment Group, Captivate Music and The Royalty Network, Inc.

For interviews, photos and other requests, contact:

Michael Freudenberger (CEO)

Captivate Music Label

Address: Otto-Hirsch-Str. 27

71686 Remseck, Germany.

Contact: [email protected]

Tel: 0049 163 6968 003

Fax: 0049 322 22488 287

linkedin.com/captivatemusic

Click Here for More Information »

DORAL, Fla., Nov. 26, 2014 /PRNewswire/ — Vitel Mobile, Inc. hosted Samsung’s GALAXY Note 4 Launch party at their new 78,000 SQ FT office and facility in Doral, Florida on Friday, November 21, 2014. Guests were given the full GALAXY Note 4 experience through larger than life stilt walking greeters, fluidic contortionists, exotic Samba dancers and Miami’s most hip DJ.  (photos of the Event – http://indiraphotography.pixieset.com/vitelmobile-samsunggalaxynote4event/ )

“Vitel Mobile, Inc. looks forward to continuing its great relationship with Samsung and is very excited to launch the new GALAXY Note 4,” said Mr. Rommey Bahhur, Vitel Mobile, Inc. CEO.  Vitel Mobile, Inc.’s staff has kicked it into full gear to make sure it has sufficient inventory to offer it is customers all of the latest Samsung models at the best price for this 2014 holiday shopping season.

About Vitel Mobile:
Established and managed by Industry Veterans since 2009, Vitel Mobile, Inc. has a cohesive sales and distribution channel that serves every country in Latin America and the Caribbean markets.  Vitel Mobile, Inc.’s headquarters is located in Miami, Florida; however, has global presence in Panama, Korea, China, Dubai and Israel.

Contact
Media and Marketing Relations:
8950 NW 27 ST
Doral, FL 33172
(305)418-9790
Natalia Aristizabal
[email protected]

Click Here for More Information »

WILMINGTON, Del., Oct. 27, 2014 /PRNewswire/ – The following statement is being issued regarding the In re Specialty Products Holding Corp. matter (Case No. 10-11780 (PJW) (Bankr. D. Del. 2010).

A Joint Plan of Reorganization (”Plan”) has been filed to reorganize Specialty Products Holding Corp. (formerly known as RPM, Inc.), Bondex International, Inc., Republic Powdered Metals, Inc., and NMBFiL, Inc. (formerly known as Bondo Corporation) (collectively, “Debtors”) in the United States Bankruptcy Court for the District of Delaware (”Bankruptcy Court”).

Persons or entities with asbestos related personal injury claims against any of the Debtors may vote to accept or reject the Plan by December 2, 2014.

A detailed document describing the Plan, called the Disclosure Statement, was approved by the Bankruptcy Court on October 20, 2014.  The Disclosure Statement, a copy of the Plan itself and voting materials have been sent to known holders of asbestos related personal injury claims against the Debtors or to their lawyers.

Important Plan Provisions Regarding Asbestos Related Claims

The Plan proposes establishing a trust to resolve all asbestos personal injury claims against the Debtors.  Persons and entities with asbestos personal injury or related claims will be forever barred from asserting their claims against the Debtors or other parties specified in the Plan. If the Plan is approved by the Court, all current and future holders of asbestos personal injury claims against the Debtors can request and receive money only from the trust.  You should read the Plan and Disclosure Statement carefully for details about how the Plan, if approved, will affect your rights.

Voting Procedures

The Bankruptcy Court has issued an order describing how to vote on the Plan and the Disclosure Statement contains information that will help you decide how to vote.  Your legal rights will be affected if the Plan is approved.  For a vote to be counted, a ballot must be received at the address indicated on the ballot form by 5:00 p.m., Eastern time, on December 2, 2014.

Under the procedures approved by the Bankruptcy Court, lawyers for holders of asbestos claims may vote on the Plan on behalf of their clients, if authorized by the client.  If you are unsure whether your lawyer is authorized to vote on your behalf, please contact your lawyer.

How to Obtain Documents

Copies of the Disclosure Statement, which includes the Plan, the voting materials, and the notice of the hearing to consider confirmation of the Plan may be obtained by visiting the following websites:  www.deb.uscourts.gov and www.loganandco.com.  You may also obtain copies of these documents by sending a request, in writing, to Logan & Company, Inc., 546 Valley Road, Upper Montclair, NJ 07043 (Attn: SPHC Voting Department) or by calling 1-866-692-2119.

Confirmation Hearing

A hearing to consider confirmation of the Plan has been scheduled for December 10, 2014 at 3:30 pm ET in Courtroom 4B at the United States District Court for the District of Delaware, J. Caleb Boggs Federal Building, located at 844 North King Street, 4th Floor, Wilmington, Delaware 19801. You may attend the Hearing but are not required to do so.

Objecting to the Plan

If you want to object to the Plan, you must file and serve a written objection on or before 5:00 p.m. ET, on December 2, 2014. All objections must comply with the requirements in the notice of the Confirmation Hearing.

For more information and to obtain a copy of the Plan, Disclosure Statement and Voting Materials,

Visit:  www.deb.uscourts.gov OR www.loganandco.com.

Write: Logan & Company, Inc., 546 Valley Road,

Upper Montclair, NJ 07043

(Attn: SPHC Voting Department)

Call:  1-866-692-2119

CONTACT: Dan Prieto, Jones Day, 1.214.969.4515

Click Here for More Information »

Leading Workforce and Family Locator Applications Now Available for Central America Family and Enterprise Subscribers

ANNAPOLIS, Md., Oct. 16, 2013 /PRNewswire/ – TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a world leader in highly reliable and secure mobile communication technology, announced today the deployment of TCS Family Locator™ and TCS Workforce Locator™ applications for wireless subscribers of Claro, a subsidiary of America Movil, S.A.B. de C.V. By leveraging TCS’ experience and award-winning, secure and easy-to-use location applications, Claro Central America will provide an additional value-added service to personal and business subscribers. Claro Central America is branding their locator applications as Localizame Familia and Localizame Empresa.

News Facts:

• Subscribers can access these services with both GPS- and non-GPS-enabled handsets.
• These locator applications seamlessly integrate with the operator’s network location infrastructure to support handsets without GPS.
• For even more precise location and to reduce network traffic, Claro Central America has deployed TCS’ patented XLSA agent which interacts directly with GPS-capable handsets.
• Claro Central America is initially offering their Localizame Familia and Localizame Empresa applications to subscribers in Guatemala with plans to expand service throughout Central America.
• A Frost & Sullivan award winner, TCS’ end-to-end location-based services (LBS) solution provides a comprehensive applications portfolio, mapping and data servers, a robust middleware platform, location servers that support coarse and precise location for GSM and CDMA devices, and LBS Assistance Data Services.

TCS Family Locator:

• Whether a family member is indoors or outside, TCS Family Locator enables families to stay connected using the latest in positioning technologies, including assisted GPS and network-based solutions.
• Via desktop, mobile application or SMS, subscribers can locate family members and receive detailed location information, including approximate address.
• TCS Family Locator allows users to pinpoint nearby points of interest and share details and directions with family and friends.
• TCS Family Locator also allows subscribers to be alerted of family member locations at predefined, scheduled times.

TCS Workforce Locator:

• TCS Workforce Locator provides greater control of mobile assets for organizations through an easy-to-use, cost-effective, web-based solution that locates specified employees, directs them to destinations and enables group communication via text messaging.
• With enhanced administrative controls, TCS Workforce Locator heightens visibility into mobile workforces, optimizes efficiency and improves response time while complying with privacy initiatives.
• Administrators can track workers on a predefined schedule or be alerted of arrivals and departures from administer-defined zones.
• Advanced features include enhanced security and the ability to delegate administrative management to field managers and regional offices.

TCS is a global leader in wireless LBS technology. It provides complete, end-to-end wireless LBS solutions that include branded and private-label applications, infrastructure, mapping and content for leading consumer brands, content providers, voice service providers and more than 70 customers worldwide. TCS developed the world’s first precise wireless location platform, and it is the industry’s leading provider of LBS infrastructure. Using innovative mobile cloud computing services, TCS offers top revenue-producing applications for navigation, hyper-local search, workforce tracking and family locators. For more information on TCS LBS services, visit http://www.telecomsys.com/products/location-based-services/apps/default.aspx

Supporting Quotes:

TCS Commercial Solutions Group President Jay Whitehurst said:
“Claro understands its subscribers’ need for trustworthy, secure applications and has taken a leadership role in helping both businesses and families. Using TCS applications, Claro continues to provide first-class service to their customers with Localizame Empresa for workers on the road and Localizame Familia to help families stay connected and protected.”

Carlos Rios, Central America Marketing Director, said:
“Many organizations are managing increasingly large mobile workforces and demanding a reliable mobile asset management solution that can be customized to their unique needs. Localizame Empresa enables organizations to conveniently locate and manage remote workers, thereby improving internal communication, efficiency, productivity, safety and security, while mitigating privacy concerns. Localizame Familia allows family users to quickly and conveniently locate and communicate with family members, as well as to easily share their location in a secure manner.

About Claro in Central America:
Claro is the only operator in the region that provides total solutions in wireless services, broadband access, cable TV and landlines, as well as the best rates and coverage in Central America.

About AMX:
AMX is the leading provider of wireless services in Latin America. As of June 30th, 2013, it had 328.8 million accesses.

About TeleCommunication Systems, Inc.
TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) is a world leader in highly reliable and secure mobile communication technology. TCS infrastructure forms the foundation for market leading solutions in E9-1-1, text messaging, commercial location and deployable wireless communications. TCS is at the forefront of new mobile cloud computing services providing wireless applications for navigation, hyper-local search, asset tracking, social applications and telematics. Millions of individuals around the world use TCS wireless apps as a fundamental part of their daily lives. Government agencies utilize TCS’ cyber security expertise, professional services, and highly secure deployable satellite solutions for mission-critical communications. Headquartered in Annapolis, MD, TCS maintains technical, service and sales offices around the world. To learn more about emerging and innovative wireless technologies, visit www.telecomsys.com.

Except for the historical information contained herein, this news release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties and are based upon TCS’ current expectations and assumptions that if incorrect would cause actual results to differ materially from those anticipated. Risks include those detailed from time to time in the Company’s SEC reports, including the report on Form 10-K year ended December 31, 2012 and on Form 10-Q for the quarter ended June 30, 2013.

Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information in this press release, whether as a result of new information, future events or circumstances, or otherwise.

(Logo: http://photos.prnewswire.com/prnh/20120503/PH99996LOGO)

Company Contact:      Claro Contact:            Media Contact:         Investor Relations:

Meredith Allen        Litza de Escoba           Nadel Phelan           Liolios Group, Inc.

410-295-1865          [email protected] Graham Sorkin          Scott Liolios

[email protected] 831-440-2406              [email protected] 949-574-3860

                                                                       [email protected]

Click Here for More Information »

Kitchen & Bath Products Leader Will Serve as Platform for North American Presence as LIXIL Continues Globalization of Business

TOKYO, June 28, 2013 /PRNewswire/ – LIXIL Corporation (Headquarters: Tokyo, Japan; President: Yoshiaki Fujimori), today announced that it has reached a definitive agreement to acquire 100% of the share capital of ASD Americas Holding Corp., the parent company of American Standard Brands (Headquarters: New Jersey, US; President and CEO: Jay Gould, hereafter called “American Standard”) at an enterprise value of $542 million (53.1 billion JPY, $1=98JPY) from an affiliate of Sun Capital Partners, Inc. (”Sun Capital”) (Headquarters: US).

American Standard is a leading North American manufacturer of a wide range of high quality kitchen and bath products.  On completion of the transaction, which is subject to regulatory approval, the company will remain headquartered in the U.S., and continue operating all existing facilities.

LIXIL Group, 1.4 trillion JPY ($15.3 billion, $1= 94.05JPY) building products company, has been actively expanding its global business.  LIXIL Group’s international sales reached approximately 200 billion JPY, contributing over 14% of the sales for the fiscal year ended March 31, 2013 and will increase to approximately 300 billion JPY comprising approximately 20% of LIXIL Group revenues. LIXIL’s global operations are present in more than 30 countries. In North America, Permasteelisa Group, a high-end curtain wall contractor owned by LIXIL Group, has existing revenues of approximately 30 billion JPY. The addition of American Standard will provide LIXIL with greater scale and more opportunities in North America, and will continue the growth of the international business towards its mid-term goals.

Yoshiaki Fujimori, President of LIXIL Corporation, said, “American Standard is the leader in the kitchen and bath products market with a deep history of more than 130 years.  LIXIL is targeting 1 trillion JPY sales revenue in its international businesses, with the goal for the international business to grow to approximately 30% of total LIXIL Group revenues.  American Standard will serve as a key platform for LIXIL as we continue to fulfill our ambitions to become a worldwide leader in the building materials and housing equipment market. LIXIL already owns the American Standard brand in the Asia Pacific market, and this transaction will strengthen the brand and the company’s considerable manufacturing capabilities and technological best practices.”

“This transaction marks an exciting chapter in our 137-year history,” said Jay Gould, American Standard Brands President and CEO. “We and our customers will surely benefit by combining LIXIL’s quality control, manufacturing technology and product development with American Standard’s sales networks, and I believe these will help the company maintain our position as a market leader.”

“The market leadership that American Standard enjoys today has been fueled by considerable operational improvements, an expanded product platform achieved through four strategic acquisitions, and a commitment to innovation,” said Marc Leder, Co-CEO at Sun Capital, a leading private investment firm specializing in leveraged buyouts and investments in market–leading companies. “I expect LIXIL will continue to invest in these strategies, and that the combined technology and product development capabilities of American Standard and LIXIL will ensure significant progress in the years ahead.”

About LIXIL Corporation
LIXIL is Japan’s largest manufacturer group for building materials and housing equipment and has more than 75,000 employees worldwide. The Group recorded net sales of 1.4 trillion JPY in FY ended March 2013. It offers comprehensive solutions in housing and lifestyle and an extensive product lineup from windows, tiles, front doors, kitchens, bathrooms, and toilets under the brand name of American Standard (Asia Pacific), INAX and Tostem.

In Japan, LIXIL is the biggest housing and building materials company with top share in eight different categories currently led by President Yoshiaki Fujimori. Those include approx. 55% share in exteriors, approx. 50% share in housing sashes/doors, approx. 50% in curtain walls and approx. 40% in sanitary wares. LIXIL also is a top brand in tiles, washstand cabinet units, bathroom units and kitchen units. LIXIL, through the integration, now has a vast and unique business portfolio.

In the global market, its operations are led by group companies, such as Permasteelisa Group, which has strong presence in the curtain wall business with unmatched technology and designs. Their projects in the US include: New York by Gehry, One Bryant Park in NY and San Francisco Federal Building.

For more information about LIXIL, please visit http://global.lixil.co.jp/

About American Standard
American Standard is a leading manufacturer of a wide range of high-quality kitchen and bath products for residential and commercial customers in the North America, Canada and Mexico. The company employs more than 5,000 people and markets products under the brand names of American Standard®, Jado®, Porcher®, Safety Tubs®, Crane Plumbing®, Eljer®, Fiat® and Decorative Panels International®.

For more information about American Standard, visit:
www.americanstandard.com
twitter.com/AmStandard
www.facebook.com/AmericanStandardPlumbing.

About Sun Capital Partners, Inc.
Sun Capital Partners, Inc. is a leading private investment firm focused on leveraged buyouts, equity, debt, and other investments in companies that can benefit from its in–house operating professionals and experience. Sun Capital affiliates have invested in more than 320 companies worldwide with combined sales in excess of $45 billion since Sun Capital’s inception in 1995. Sun Capital has offices in Boca Raton, Los Angeles, and New York, as well as affiliates in London, Paris, Frankfurt, Luxembourg, Shanghai and Shenzhen. For more information, visit www.SunCapPart.com.

Click Here for More Information »

– Voluntary recall of certain lots of Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley’s® Complete Liquids, issued to consumers, retail customers and wholesalers in Jamaica

– Consumers who may have the product(s) being recalled are asked to return the affected products and receive a full refund

– The products being recalled were produced at a Novartis Consumer Health manufacturing facility in the United States prior to the voluntary suspension of operations in December 2011, and at a third-party manufacturing site in Canada using the same bottle and cap components

PANAMA CITY, Fla., Feb. 5, 2013 /PRNewswire/ — Novartis Pharma Logistics, Inc. announced today that it is voluntarily recalling certain lots of Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley’s® Complete Liquids. Novartis Pharma Logistics has decided to issue a voluntary recall to consumers, retail customers and wholesalers in Jamaica because the child-resistant feature of the bottle cap may not function properly, enabling the cap to be removed with the tamper-evident seal still in place. The affected bottle sizes are included at the end of this release.

Novartis Pharma Logistics has not received any adverse events due to the tamper evident seal causing a failure of the child resistant cap. Novartis Consumer Health, Inc.  in the United States received four adverse events for Triaminic® Syrups related to this issue.

Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley’s® Complete Liquids continue to be safe and effective when used as directed on the package label.

The products being recalled were produced at a Novartis Consumer Health manufacturing facility in the US prior to the voluntary suspension of operations in December 2011. In addition to production at the US site, Buckley’s Complete® was also produced until January 2013 at a third-party manufacturing site in Canada. A consumer complaint in the US in late November 2012 triggered an internal investigation by Novartis Consumer Health that determined a voluntary recall was in the best interest of consumers.

Action to be taken by consumers

Novartis Pharma Logistics advises consumers who believe they have product included in this recall to discontinue use and return the recalled product to the store or pharmacy where it was purchased for a full refund.  Only recalled product in the original bottle will be eligible for a refund. Consumers may contact the Novartis Consumer Relationship Center at 877-769-8420 (available Monday-Saturday 8 a.m. to 6 p.m. Eastern Time) for more detailed information about the recall, including which products are impacted, and for information on how to return the affected products and receive a full refund.

Action to be taken by retailers and wholesalers

Retailers and wholesalers should stop distribution and return the affected lots using the Novartis Product Return information that is being provided to them. Retailers that receive product returns from consumers will be reimbursed by Novartis Pharma Logistics.

This recall is being conducted with the full knowledge of the Jamaica Ministry of Health.

Disclaimer

The foregoing release contains forward-looking statements including express or implied discussions regarding potential future revenues from Novartis OTC products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis OTC products will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

Novartis Media Relations

Julie Masow                            Milicent Brooks

Novartis Corporation                   Novartis Consumer Health, Inc.

+1 212 830 2465 (direct)                                                   +1 973 503 7483(direct)

+1 862 579 8456 (mobile)                                                  +1 973 479 2078 (mobile)

[email protected]               [email protected]

Pamela McKinlay                        Francisco Ericastilla

Novartis Consumer Health, Inc.         Novartis Farmaceutica, S.A. (AC)

+1 973 503 7337(direct)                                                    +502 242 28438 (direct)

+1 862 221 0151(mobile)                                                    +502 571 09426 (mobile)

[email protected]           [email protected]

e-mail: [email protected]

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis.
For questions about the site or required registration, please contact: [email protected].

Theraflu Warming Relief® Syrups

                  PRODUCT                              Item UPC NUMBER                    NDC NUMBER                       Case UCC NUMBER                       Size                       LOT                        EXPIRY DATE

                  -------                              ---------------                    ----------                       ---------------                       ----                       ---                        -----------

Theraflu (R) Warming Relief Flu and Sore

 Throat, 8.3 oz.                                                    300436265081                    43626508                             10300436265088  8.3 oz                                     10108935                     03/31/2013

----------------------------------------                            ------------                    --------                             --------------  ------                                     --------                     ----------

                                  10096570                            05/31/2013

                                  --------                            ----------

                                  10121298                            05/31/2013

                                  --------                            ----------

                                  10123035                            05/31/2013

                                  --------                            ----------

                                  10106483                            06/30/2013

                                  --------                            ----------

                                  10126716                            07/31/2013

                                  --------                            ----------

Theraflu(R) Daytime Warming Relief Severe

 Cold and Cough, 8.3 oz.                                            300430461083                    43046108                             10300430461080  8.3 oz                                     10096571                     04/30/2013

-----------------------------------------                           ------------                    --------                             --------------  ------                                     --------                     ----------

                                  10117845                            04/30/2013

                                  --------                            ----------

                                  10102070                            06/30/2013

                                  --------                            ----------

                                  10118134                            06/30/2013

                                  --------                            ----------

                                  10118135                            08/31/2013

                                  --------                            ----------

                                  10126586                            08/31/2013

                                  --------                            ----------

                                  10126729                            10/31/2013

                                  --------                            ----------

Theraflu(R) Daytime/Nighttime Severe Cold

 & Cough Value Pack                                                 300436412164                    67641216                             10300436412161                                             10120065                     03/01/2013

-----------------------------------------                           ------------                    --------                             --------------                                             --------                     ----------

10116591A                                                             03/13/2013

---------                                                             ----------

                                  10116591                            03/31/2013

                                  --------                            ----------

                                  10116593                            03/31/2013

                                  --------                            ----------

                                  10106487                            05/31/2013

                                  --------                            ----------

                                  10108285                            05/31/2013

                                  --------                            ----------

                                  10116594                            06/30/2013

                                  --------                            ----------

                                  10116597                            06/30/2013

                                  --------                            ----------

                                  10116598                            06/30/2013

                                  --------                            ----------

                                  10116600                            06/30/2013

                                  --------                            ----------

                                  10116601                            08/31/2013

                                  --------                            ----------

                                  10116602                            08/31/2013

                                  --------                            ----------

Theraflu(R) Nighttime Warming Relief

 Severe Cold and Cough, 8.3 oz.                                     300430460086                    43046008                             10300430460083  8.3 oz                                     10104954                     04/30/2013

------------------------------------                                ------------                    --------                             --------------  ------                                     --------                     ----------

                                  10104955                            05/31/2013

                                  --------                            ----------

                                  10107018                            05/31/2013

                                  --------                            ----------

                                  10118113                            05/31/2013

                                  --------                            ----------

                                  10123039                            05/31/2013

                                  --------                            ----------

                                  10104956                            07/31/2013

                                  --------                            ----------

                                  10126861                            08/31/2013

                                  --------                            ----------

Theraflu(R) Warming Relief Cold and Chest

 Congestion, 8.3 oz.                                                300436296085                    43629608                             10300436296082  8.3 oz                                     10106482                     01/31/2013

-----------------------------------------                           ------------                    --------                             --------------  ------                                     --------                     ----------

                                  10102071                            07/31/2013

                                  --------                            ----------

                                  10113497                            07/31/2013

                                  --------                            ----------

                                  10122891                            08/31/2013

                                  --------                            ----------

                                  10123274                            08/31/2013

                                  --------                            ----------

                                  10126440                            09/30/2013

                                  --------                            ----------

                                  10128457                            11/30/2013

                                  --------                            ----------

Theraflu(R) Warming Relief Sinus and Cold,

 8.3 oz.                                                            300436407085                    67640708                             10300436407082  8.3 oz                                     10095358                     04/30/2013

------------------------------------------                          ------------                    --------                             --------------  ------                                     --------                     ----------

                                  10104966                            07/31/2013

                                  --------                            ----------

Triaminic® Syrups

                  PRODUCT                       Item UPC

                                                 NUMBER       NDC NUMBER    Case UCC NUMBER         Size                    LOT                      EXPIRY DATE

                  -------                         --------    ----------    ---------------         ----                    ---                      -----------

Triaminic(R) Cold and Allergy, 4 oz.          300436346049        67634604    10300436346046  4 oz                                10092519                     01/31/2013

------------------------------------          ------------        --------    --------------  ----                                --------                     ----------

                                  10096507                        02/28/2013

                                  --------                        ----------

                                  10092518                        04/30/2013

                                  --------                        ----------

                                  10102344                        05/31/2013

                                  --------                        ----------

                                  10102052                     06/30/2013

                                  --------                     ----------

                                  10098505                     07/31/2013

                                  --------                     ----------

                                  10106511                     11/30/2013

                                  --------                     ----------

                                  10099191                     12/31/2013

                                  --------                     ----------

                                  10122929                     02/28/2014

                                  --------                     ----------

                                  10125956                     05/31/2014

                                  --------                     ----------

Triaminic(R) Cough and Sore Throat, 4 oz.     300436348043        67634804    10300436348040  4 oz                                10104678                     02/28/2013

-----------------------------------------     ------------        --------    --------------  ----                                --------                     ----------

                                  10107025                     02/28/2013

                                  --------                     ----------

                                  10107026                     05/31/2013

                                  --------                     ----------

                                  10117681                     06/30/2013

                                  --------                     ----------

                                  10118052                     08/31/2013

                                  --------                     ----------

                                  10126850                     09/30/2013

                                  --------                     ----------

Triaminic(R) Day Time Cold and Cough, 4

 oz.                                          300436345042        67634504    10300436345049  4 oz                                10092520                     01/31/2013

---------------------------------------       ------------        --------    --------------  ----                                --------                     ----------

                                  10095545                     01/31/2013

                                  --------                     ----------

                                  10117453                     02/28/2013

                                  --------                     ----------

                                  10097308                     03/31/2013

                                  --------                     ----------

                                  10095904                     04/30/2013

                                  --------                     ----------

                                  10099699                     05/31/2013

                                  --------                     ----------

                                  10102053                     06/30/2013

                                  --------                     ----------

                                  10103616                     07/31/2013

                                  --------                     ----------

                                  10107024                     08/31/2013

                                  --------                     ----------

                                  10103617                     09/30/2013

                                  --------                     ----------

                                  10114266                     10/31/2013

                                  --------                     ----------

                                  10116660                     11/30/2013

                                  --------                     ----------

                                  10116869                     12/31/2013

                                  --------                     ----------

                                  10116870                     02/28/2014

                                  --------                     ----------

                                  10126445                     03/31/2014

                                  --------                     ----------

Triaminic(R) Daytime/Nighttime Cold &

 Cough Club Pack                              300436417121             N/A    10300436417135                                      10095327                     01/31/2013

-------------------------------------         ------------             ---    --------------                                      --------                     ----------

                                  10095907                     01/31/2013

                                  --------                     ----------

                                  10097748                     01/31/2013

                                  --------                     ----------

                                  10095298                     04/30/2013

                                  --------                     ----------

                                  10117817                     12/31/2013

                                  --------                     ----------

                                  10117818                     03/31/2014

                                  --------                     ----------

                                  10117819                     03/31/2014

                                  --------                     ----------

Triaminic(R) Daytime/Nighttime Cold &

 Cough Combo Pack                             300436216083        67621608                                                        10095906                     01/31/2013

                                                                              10300436216080

---

                                  10099216                     02/28/2013

                                  --------                     ----------

                                  10100792                     04/30/2013

                                  --------                     ----------

                                  10100793                     04/30/2013

                                  --------                     ----------

                                  10101494                     05/31/2013

                                  --------                     ----------

                                  10101495                     05/31/2013

                                  --------                     ----------

                                  10106846                     05/31/2013

                                  --------                     ----------

                                  10104675                     06/30/2013

                                  --------                     ----------

                                  10106086                     06/30/2013

                                  --------                     ----------

                                  10106088                     07/31/2013

                                  --------                     ----------

                                  10106284                     07/31/2013

                                  --------                     ----------

                                  10106848                     08/31/2013

                                  --------                     ----------

                                  10110968                     08/31/2013

                                  --------                     ----------

                                  10113146                     09/30/2013

                                  --------                     ----------

                                  10113147                     11/30/2013

                                  --------                     ----------

                                  10115037                     11/30/2013

                                  --------                     ----------

                                  10116592                     12/31/2013

                                  --------                     ----------

Triaminic® Syrups (Cont.)

                  PRODUCT                       Item UPC

                                                 NUMBER             NDC NUMBER          Case UCC NUMBER           Size                     LOT                      EXPIRY DATE

                  -------                         --------          ----------          ---------------           ----                     ---                      -----------

Triaminic(R) Daytime/Nighttime Cold &

 Cough Combo Pack (Cont.)                     300436216083                    67621608    10300436216080                                         10116595                     12/31/2013

-------------------------------------         ------------                    --------    --------------                                         --------                     ----------

10116596                                        12/31/2013

--------                                        ----------

10116599                                        03/31/2014

--------                                        ----------

10123383                                        03/31/2014

--------                                        ----------

10123388                                        03/31/2014

--------                                        ----------

Triaminic(R) Dye-free Long Acting Cough,

 4 oz.                                        300436350046                    67635004    10300436350043  4 oz                                   10081942                     04/30/2013

----------------------------------------      ------------                    --------    --------------  ----                                   --------                     ----------

10082283                                        04/30/2013

--------                                        ----------

10081940                                        06/30/2013

--------                                        ----------

10097082                                        07/31/2013

--------                                        ----------

10082927                                        09/30/2013

--------                                        ----------

10095893                                        10/31/2013

--------                                        ----------

10095894                                        10/31/2013

--------                                        ----------

10102049                                        11/30/2013

--------                                        ----------

10102048                                        12/31/2013

--------                                        ----------

10106251                                        12/31/2013

--------                                        ----------

10102051                                        01/31/2014

--------                                        ----------

10107021                                        02/28/2014

--------                                        ----------

10107022                                        05/31/2014

--------                                        ----------

10118430                                        07/31/2014

--------                                        ----------

10121529                                        08/31/2014

--------                                        ----------

10129170                                        11/30/2014

--------                                        ----------

Triaminic(R) Fever Reducer Pain Reliever

 Bubblegum, 4 oz.                             300436432049                    67643204    10300436432046  4 oz                                   10093941                     01/31/2013

----------------------------------------      ------------                    --------    --------------  ----                                   --------                     ----------

10102270                                        02/28/2013

--------                                        ----------

10112423                                        03/31/2013

--------                                        ----------

10106334                                        05/31/2013

--------                                        ----------

10116891                                        08/31/2013

--------                                        ----------

Triaminic(R) Fever Reducer Pain Reliever

 Grape, 4 oz.                                 300436431042                    67643104    10300436431049  4 oz                                   10092719                     01/31/2013

----------------------------------------      ------------                    --------    --------------  ----                                   --------                     ----------

10108530                                        02/28/2013

--------                                        ----------

10112422                                        03/31/2013

--------                                        ----------

10106335                                        05/31/2013

--------                                        ----------

10093939                                        08/31/2013

--------                                        ----------

10126470                                        10/31/2013

--------                                        ----------

10127629                                        11/30/2013

--------                                        ----------

10130550                                        11/30/2013

--------                                        ----------

Triaminic(R) Fever Reducer Pain Reliever

 Infant Bubblegum, 2 oz.                      300676441597                    67644159    10300676441594  2 oz                                   10115515                     05/31/2013

----------------------------------------      ------------                    --------    --------------  ----                                   --------                     ----------

10115516                                        05/31/2013

--------                                        ----------

10115520                                        05/31/2013

--------                                        ----------

10115521                                        05/31/2013

--------                                        ----------

10119567                                        09/30/2013

--------                                        ----------

10128589                                        11/30/2013

--------                                        ----------

Triaminic(R) Fever Reducer Pain Reliever

 Infant Grape, 2 oz.                          300676440590                    67644059    10300676440597  2 oz                                   10115517                     05/31/2013

----------------------------------------      ------------                    --------    --------------  ----                                   --------                     ----------

10115518                                        05/31/2013

--------                                        ----------

10115519                                        05/31/2013

--------                                        ----------

10115522                                        05/31/2013

--------                                        ----------

10123421                                        09/30/2013

--------                                        ----------

10128599                                        11/30/2013

--------                                        ----------

10130570                                        11/30/2013

--------                                        ----------

Triaminic(R) Multi Symptom Fever, 3.4 oz.     300676394343                    67639434    10300676394340  3.4 oz                                 10116856                     06/30/2013

-----------------------------------------     ------------                    --------    --------------  ------                                 --------                     ----------

10116857                                        06/30/2013

--------                                        ----------

10126948                                        09/30/2013

--------                                        ----------

Triaminic® Syrups (Cont.)

           PRODUCT Item UPC NUMBER           NDC NUMBER         Case UCC NUMBER                     Size LOT          EXPIRY DATE

           ------- ---------------           ----------         ---------------                     ---- ---          -----------

Triaminic(R)

 Multi

 Symptom

 Fever, 4 oz.                   300436394040           67639404               10300436394047 4 oz            10110769           02/28/2013

-------------                   ------------           --------               -------------- ----            --------           ----------

10095563                          03/31/2013

--------                          ----------

10102058                          03/31/2013

--------                          ----------

10102271                          05/31/2013

--------                          ----------

10116866                          06/30/2013

--------                          ----------

10116867                          06/30/2013

--------                          ----------

10116868                          06/30/2013

--------                          ----------

10121656                          08/31/2013

--------                          ----------

10126740                          10/31/2013

--------                          ----------

10128836                          11/30/2013

--------                          ----------

Triaminic(R)

 Night Time

 Cold and

 Cough, 3.4

 oz.                            300436344342           67634434               10300436344349 3.4 oz          10097303           03/31/2013

------------                    ------------           --------               -------------- ------          --------           ----------

10097552                          04/30/2013

--------                          ----------

10097554                          06/30/2013

--------                          ----------

10108819                          08/31/2013

--------                          ----------

10114273                          12/31/2013

--------                          ----------

10126947                          03/31/2014

--------                          ----------

Triaminic(R)

 Night Time

 Cold and

 Cough, 4 oz.                   300436344045           67634404               10300436344042 4 oz            10094309           01/31/2013

-------------                   ------------           --------               -------------- ----            --------           ----------

10095895                          03/31/2013

--------                          ----------

10097312                          04/30/2013

--------                          ----------

10097313                          04/30/2013

--------                          ----------

10104673                          05/31/2013

--------                          ----------

10102054                          06/30/2013

--------                          ----------

10106850                          07/31/2013

--------                          ----------

10108823                          08/31/2013

--------                          ----------

10111184                          08/31/2013

--------                          ----------

10101373                          11/30/2013

--------                          ----------

10114269                          12/31/2013

--------                          ----------

10118449                          12/31/2013

--------                          ----------

10121342A                         12/31/2013

---------                         ----------

10121812                          02/28/2014

--------                          ----------

10106851                          03/31/2014

--------                          ----------

10126742                          05/31/2014

--------                          ----------

Triaminic® Syrups (Cont.)

                                                  PRODUCT Item UPC NUMBER       DIN    SCC                   Size    LOT

                                                  ------- ---------------       ---    ---                   ----    ---

Triaminic Chest & Nasal Congestion - Tropical Fruit                  58478 10163 7 2278308  20058478101631 100 mL All

---------------------------------------------------                  ------------- -------  -------------- ------ ---

Triaminic Cold & Cough- Cherry                                       58478 47100 6 2243739  20058478471000 100 mL All

------------------------------                                       ------------- -------  -------------- ------ ---

Triaminic Cold & Nighttime Cough - Grape                              58478 47102 0 896179  20058478471024 100 mL All

----------------------------------------                              ------------- ------  -------------- ------ ---

Triaminic Cough & Sore Throat - Grape                                58478 47108 2 2130564  20058478471086 100 mL All

-------------------------------------                                ------------- -------  -------------- ------ ---

Triaminic Long Acting Cough - Berry Punch                            58478 10168 2 2277972 200058478101686 100 mL All

-----------------------------------------                            ------------- ------- --------------- ------ ---

Triaminic Total Cold, Cough & Fever - Bubble Gum                      58478 47104 4 2239666 20058478471048 100 mL All

------------------------------------------------                      ------------- ------- -------------- ------ ---

Buckley´s® Complete Liquids

                                                    PRODUCT Item UPC NUMBER       DIN     SCC                  Size    LOT

                                                    ------- ---------------       ---     ---                  ----    ---

Buckley's Complete with Mucus Relief Extra Strength                     58478 10792 9 2357232 20058478107923 150 mL All

---------------------------------------------------                     ------------- ------- -------------- ------ ---

Buckley's Complete with Mucus Relief Extra Strength                     58478 10776 9 2357232 20058478107763 250 mL All

---------------------------------------------------                     ------------- ------- -------------- ------ ---

Buckley's Complete PM - Nighttime                                       58478 10777 6 2356457 20058478107770 150 mL All

---------------------------------                                       ------------- ------- -------------- ------ ---

Buckley's Complete                                                      58478 10295 5 2279703 20058478102959 250 mL All

------------------                                                      ------------- ------- -------------- ------ ---

Buckley's Complete                                                      58478 10295 5 2279703 20058478102959 250 mL All

------------------                                                      ------------- ------- -------------- ------ ---

Buckley's Complete                                                      58478 10064 7 2279703 20058478100641 150 mL All

------------------                                                      ------------- ------- -------------- ------ ---

Buckley's Complete                                                      58478 10064 7 2279703 20058478100641 150 mL All

------------------                                                      ------------- ------- -------------- ------ ---

Jack & Jill® Pediatric Syrups

                                                   PRODUCT Item UPC NUMBER       DIN     SCC                  Size    LOT

                                                   ------- ---------------       ---     ---                  ----    ---

Jack & Jill Bedtime - Grape                                            65515 00010 5 2241167 10065515000102 100 mL All

---------------------------                                            ------------- ------- -------------- ------ ---

Jack & Jill Cough & Cold – Cherry                                      65515 00021 1 2242588 10065515000218 100 mL All

---------------------------------                                      ------------- ------- -------------- ------ ---

Jack & Jill Children's Formula Cough Liquid - Cherry                   65515 00019 8  823023 10065515000195 100 mL All

----------------------------------------------------                   -------------  ------ -------------- ------ ---

Jack & Jill Cough Syrup - Raspberry                                    65515 00008 2  622036 10065515000089 100 mL All

-----------------------------------                                    -------------  ------ -------------- ------ ---

Jack & Jill Expectorant - Raspberry                                    58478 10798 1 2350084 20058478107985 100 mL All

-----------------------------------                                    ------------- ------- -------------- ------ ---

Click Here for More Information »

Distinctive my choice ® Program Offers Guests Unmatched Choice of Iconic Benefits: Atlantis, Paradise Island Joins Mercedes-Benz Automobiles, Wynn Las Vegas, Royal Caribbean Cruises as Premier Options for Players

LAS VEGAS, April 30, 2012 /PRNewswire/ – Pinnacle Entertainment, Inc. (NYSE: PNK) today announced it is offering players a wealth of extraordinary benefits in its mychoice guest loyalty program. Just one year after enhancing the program, Pinnacle is now offering an innovative new benefit: annual trips to Atlantis, Paradise Island resort in The Bahamas. Atlantis joins an array of iconic brands already available to mychoice members such as the opportunity to earn an annual lease on Mercedes-Benz vehicles, cruises on Royal Caribbean International and stays at Wynn Las Vegas and Encore.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/55465-pinnacle-entertainment-mychoice-casino-rewards-program

(Photo: http://photos.prnewswire.com/prnh/20120430/MM96119 )

“Our steadfast focus remains on exceeding our guest’s expectations and truly rewarding their loyalty,” said Pinnacle Entertainment President and Chief Executive Officer Anthony Sanfilippo. “One of the many features that make the mychoice program special is that our guests design it every time they choose their own custom gifts and inspiring experiences from an unprecedented roster of world-class brands. It really is their program and we show our appreciation by offering rewards tailor-made to them; it gives choice a whole new meaning.”

“Atlantis is excited to be partnering with Pinnacle Entertainment’s mychoice loyalty program,” said George Markantonis, President/Managing Director of Kerzner International Bahamas.  “We are looking forward to welcoming their guests to the Atlantis family, offering unprecedented amenities including the largest casino in the Caribbean, beautiful white-sand beaches, world-class dining experiences and more.” 

As a new Pinnacle partner for 2012, Atlantis Resort offers an unparalleled casino experience including the Caribbean’s largest casino with a variety of 750 slots and over 90 table games, outdoor gaming at Cain at The Cove as well as a high-energy Race and Sports Book.

Pinnacle’s most loyal guests earn a place in The Owner’s Club and may apply for membership in the Owner’s Club Stock Program. Accepted guests will receive an award of 100 shares of Pinnacle common stock.  Existing Owner’s Club members may now also choose from a selection of luxury timepieces, a lease on a Mercedes-Benz sedan, SUV or convertible or an exclusive once-in-a-lifetime trip such as the Mercedes-Benz Driving Academy or an adventurous cruise featuring exotic ports of call throughout Asia.

All mychoice members earn tier points based on the games they play, the duration they play and the average bet they make. To maximize the program’s value and flexibility, casino play earns more than points toward a specific tier; it also earns members mycash rewards, which can be used for the benefits that guests enjoy most – slot play, dining, shopping, hotel stays, cash back or a combination thereof. 

In addition to the aforementioned rewards, the enhanced mychoice program features guaranteed monthly mycash multipliers, invitations to private VIP events, priority restaurant seating, VIP lounge access, personal casino hosting, preferred hotel booking and check-in and VIP seating for many high-demand entertainment events. A full description of the program is available at www.pinnaclemychoice.com.

About Pinnacle Entertainment
Pinnacle Entertainment, Inc. owns and operates six casinos, located in Louisiana, Missouri, and Indiana, and a racetrack in Ohio.  In addition, Pinnacle is developing L’Auberge Casino Hotel Baton Rouge, and holds a 26% ownership stake in Asian Coast Development (Canada) Ltd. (ACDL), an international development and real estate company currently developing Vietnam’s first large-scale integrated resort on the Ho Tram Strip.

Pinnacle Entertainment, Inc. is publicly traded on the New York Stock Exchange under the ticker symbol PNK.  To learn more about Pinnacle Entertainment, please visit www.pnkinc.com.

Forward-Looking Statements
All statements included in this press release, other than historical information or statements of historical fact, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements, including statements regarding the mychoice program, the Owner’s Club and the Owners Club Stock Program, are based on management’s current expectations and are subject to risks, uncertainties and changes in circumstances that could significantly affect future results.  Accordingly, Pinnacle cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements.  For more information on the potential factors that could affect Pinnacle’s business and financial results, review Pinnacle’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Pinnacle Entertainment, Inc. has filed a registration statement (including a prospectus) on Form S-3 (File No. 333-172884) with the SEC for the offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering.  You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.  Alternatively, Pinnacle Entertainment, Inc. will arrange to send you the prospectus if you request it by calling toll-free 1-877-764-8750.

Click Here for More Information »

SAN DIEGO, Jan. 12, 2012 /PRNewswire/ – Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease. MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. This initial study will involve patients who are not currently undergoing a painful vaso-occlusive crisis. Preclinical studies show that carbon monoxide stabilizes the hemoglobin of patients with sickle cell disease and prevents the sickling of red blood cells.

“We are encouraged by the preclinical data on MP4CO and look forward to evaluating the safety and potential efficacy of this therapy in helping alleviate pain associated with a sickle cell crisis, while also potentially reducing the severity and duration of a crisis,” said Dr. Jo Howard, at Guy’s and St Thomas’ Hospital, London, UK. “There is currently a dearth of treatments for painful vaso-occlusive crises associated with sickle cell disease, and MP4CO represents a potential treatment option for these patients.”

The clinical trial is a multi-center, randomized, double-blind, controlled study that will enroll approximately 32 clinically stable adult patients with sickle cell disease who are not undergoing a painful vaso-occlusive crisis. The trial will be conducted at four sites across three countries, including the United Kingdom, France and Jamaica. The primary objective of the study is to establish the safety of treatment with MP4CO. The study will comprise ascending dose levels in five groups of single dose infusions followed by three groups of fractionated doses.

“This trial initiation is a key step towards providing a treatment to patients suffering from a sickle cell crisis. The strong preclinical data suggest that a clinical evaluation of MP4CO in patients could yield meaningful results,” said Brian O’Callaghan, President and CEO of Sangart. “Along with our other investigational therapy, MP4OX, we remain committed to developing medicines designed to enhance the delivery of oxygen and other gases to tissues and organs.”

Sickle cell disease is an inherited hemoglobin disorder affecting red blood cell circulation in millions of people around the world. People with sickle cell disease have red blood cells that contain mostly hemoglobin S, an abnormal type of hemoglobin. Due to the presence of hemoglobin S, these red blood cells become crescent or sickle-shaped and have difficulty passing through small blood vessels. When sickle-shaped cells block small blood vessels, less blood circulates through the body, causing severe pain and damage to tissues that do not receive a normal blood flow. This vaso-occlusion is known as a “sickle cell crisis”.  There are currently no approved medications to treat sickle cell crises, and only symptomatic relief is available.

About MP4
Sangart’s product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia. MP4 can bind carbon monoxide for delivery to hemoglobin in red blood cells and heme proteins in tissues to provide anti-inflammatory and anti-apoptotic (anti-programmed cell death) effects. Once carbon monoxide has been released, MP4 takes up oxygen, when circulating through the lung, for delivery to ischemic tissues.

About Sangart
Sangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Based on more than a decade of research, Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen through the circulatory system to prevent and treat ischemia, or carbon monoxide to prevent and reverse sickling and its consequences.

To learn more about Sangart, please visit the company’s website at www.sangart.com.

Click Here for More Information »

HALIFAX, Nova Scotia, Jan. 25, 2011 /PRNewswire/ — Emera Inc. (”Emera” – Toronto Stock Exchange listing “EMA”) wishes to advise all shareholders of Light & Power Holdings Ltd. (”Light & Power Holdings” – Barbados Stock Exchange listing: “LPH”) that the offer to purchase all issued and outstanding common shares in Light & Power Holdings at a cash price per share of BB$25.70 (twenty five Barbados dollars and seventy Barbados cents) closed as of 5 pm on January 24, 2011.

 7,129,269 shares of LPH were deposited in response to the offer and Emera announced today that it will purchase all deposited shares. If the tender and acceptance of all shares is confirmed by the Barbados Stock Exchange as valid, this will increase Emera’s ownership in LPH to 79.74 per cent.

 This 41.43 per cent additional investment will make Emera the majority shareholder in LPH. The remaining shares of LPH are primarily held by 1,700 Barbadian shareholder accounts, including the National Insurance Board of Barbados.

 Payments for deposited shares will be made to shareholders by January 31, 2011. The transaction is expected to close in the first quarter.

 Light & Power Holdings is the parent company of The Barbados Light & Power Company Limited (”BLPC”). BLPC is the sole electric utility operator on the island of Barbados, serving 120,000 customers. BLPC has three power generation stations consisting of 239 MW of installed capacity.

 Cautionary Statement Regarding Forward-Looking Information:

 This release contains forward-looking information and should not be read as a guarantee of future events, performance or results, and will not necessarily be an accurate indication of whether, or the times at which, such events, performance or results will be achieved. Emera disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

 About Emera

 (EMA and EMA.PR.A – TSX) is an energy and services company with $5.8 billion Canadian dollars in assets. Electricity is Emera’s core business. Approximately 94% of Emera’s revenues are earned by Nova Scotia Power Inc (NSPI), Bangor Hydro Electric Company (BHE) and the Brunswick Pipeline. NSPI and BHE are wholly-owned regulated electric utilities which together serve 603,000 customers. The Brunswick Pipeline is a 145 km gas pipeline in New Brunswick. Emera also owns Maine and Maritimes Corporation, the parent company of Maine Public Service Company, a regulated electric utility serving approximately 36,000 electricity customers in Northern Maine, and MAM Services Group. In the Caribbean, Emera owns 19% of St. Lucia Electricity Services Limited, which serves more than 50,000 customers on the island of St. Lucia; 80.4% of Grand Bahama Power Company which serves 19,000 customers on the island of Grand Bahama; and 38% of Light & Power Holdings which serves 120,000 customers on the island of Barbados through its regulated electric utility The Barbados Light and Power Company. As well, Emera owns 8.2% of Algonquin Power & Utilities Corp. and 50% of Calpeco which serves 47,000 customers in California. In addition to its electric utility investments, Emera owns Bayside Power, a 260 MW gas-fired power plant in Saint John, New Brunswick; Emera Energy Services, a physical natural gas and power marketing and asset management business; a joint venture interest in Bear Swamp, a 600 megawatt pumped storage hydro-electric facility in northern Massachusetts; a 12.9% interest in the Maritimes & Northeast Pipeline; and an 8.2% interest in Open Hydro. Visit Emera on the web at www.emera.com .

 (EMA.)

Click Here for More Information »

$50,000 in Guaranteed Prizes

 NEW YORK and LAS VEGAS, March 9 /PRNewswire/ — DominoesStars.com, Hornitos Tequila, DominoUSA, NPDPA and R. Paniagua, Inc. present the FID World Domino Championship at the Las Vegas Hilton, Memorial Day weekend May 26th – 29th with guaranteed prizes of $50,000.

 A classic “Double Six” tournament will be supervised by the DominoUSA Federation. The “High Five” tournament will be administered by domino legend Travis Newsome, President of the NPDPA.

 ”Hundreds of players from all over the world have confirmed their participation,” said Manny Oquendo, President of DominoUSA Federation.

 ”We are elated to have the High Five version of dominoes as part of this prestigious tournament. We look at this as the beginning of a great, long term marriage between High Five and Classic Six domino tournaments,” Mr. Newsome added.

 R. Paniagua, Inc. and DominoUSA will produce the World Domino Championship event at the Las Vegas Hilton.

 RPI first presented the World Domino Tournament at the Hilton and aired the tournaments on T.V. “Now with the alliance forged with the two leading organizations that represent the major style of domino play, this event will continue being the # 1 tournament in quality and fair play. In addition the tournament guarantees its cash prizes,” said Ralph Paniagua, RPI’s President.

 ”And with the event taking place over the Memorial Day weekend, the players and their families will have the opportunity to enjoy Las Vegas,” concluded Paniagua.

 The event is sponsored by DominoesStars.com, the online home of Dominoes and Hornitos Tequila.

 Participants and their guests are being offered an $89.00 daily rate with breakfast.

 For Hotel Reservations contact the Hilton (Idalia or Rose): Direct (702) 732-5060. Toll Free U.S. 1-866-278-6712; Mexico 001-866-278-6712; Venezuela 0-800-100-2630.

 TRADITIONAL DOUBLE-SIX CHAMPIONSHIP: Manuel Oquendo: 407-252-2689; Lucas Guittard – Venezuela: + 58 414-326-36-06; Ralph Paniagua: 212-679-6755; Ricardo Arias – Mexico: 001-521-686-569-3553 or visit DominoUSA.org or VivaDomino.com.

 HIGH FIVE TOURNAMENT: Travis Newsome 816-536-1962 [email protected]. Learn to play dominoes or register online at: www.DominoesStars.com.

 For further information please visit DominoesStars.com, DominoUSA.org and VivaDomino.com.

Click Here for More Information »